Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics PCSK9 Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    PCSK9 Inhibitors Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and quantity-limit approval for Praluent, Repatha formulations, Lerochol, and Lipfendra for commercial plan members. It establishes covered indications, statin-use or intolerance requirements, preferred-agent rules, continuation criteria, and quantity-limit exceptions.

    Policy Summary
    PayerPrime Therapeutics
    PolicyPCSK9 Inhibitors Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 19, 2026
    Next Review DateN/A
    Key ActionSubmit documentation supporting the diagnosis, LDL-C values, ASCVD history, statin treatment or intolerance, and the requested agent's indication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6Targeted product formulations or agents
    2Preferred agents
    2Non-preferred agents
    12 monthsAuthorization duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6Quantity-limit product entries

    Coverage Criteria

    Initial Therapy

    Target Agent(s) will be approved when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • Homozygous familial hypercholesterolemia (HoFH)

        • The requested agent is Praluent or Repatha.
        • ONE of the following

          • HoFH is confirmed by genetic confirmation of bi-allelic pathogenic or likely pathogenic variants on different chromosomes at the LDLR, Apo-B, PCSK9, or LDLRAP1 genes, or greater than or equal to 2 such variants at different loci.
          • ALL of the following

            • History of untreated LDL-C greater than 400 mg/dL.
            • ONE of the following

              • Cutaneous or tendon xanthomas before 10 years of age.
              • Untreated LDL-C levels consistent with familial hypercholesterolemia in at least one parent.
      • Heterozygous familial hypercholesterolemia (HeFH)

        • ONE of the following

          • Genetic confirmation of one mutant allele at the LDLR, Apo-B, PCSK9, or LDLRAP1 gene.
          • Pre-treatment LDL-C greater than 190 mg/dL.
          • Clinical manifestations of HeFH, such as cutaneous xanthomas, tendon xanthomas, or corneal arcus.
          • Definite or possible familial hypercholesterolemia as defined by Simon Broome criteria.
          • Dutch Lipid Clinic Network Criteria score greater than 5.
          • Treated LDL-C level greater than or equal to 100 mg/dL after statin treatment with or without ezetimibe.
      • Hypercholesterolemia.
      • Reduction in the risk of MACE, including cardiovascular death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization; the requested agent is Praluent or Repatha.
      • Clinical atherosclerotic cardiovascular disease (ASCVD)

        • ONE of the following

          • Acute coronary syndrome.
          • History of myocardial infarction.
          • Stable or unstable angina.
          • Coronary or other arterial revascularization.
          • Stroke.
          • Transient ischemic attack.
      • The patient has another FDA-labeled indication for the requested agent and route of administration.
      • The patient has an indication supported in compendia for the requested agent and route of administration.
    • ONE of the following

      • ALL of the following

        • The patient is taking a maximally tolerated statin.
        • The patient will continue statin therapy in combination with the requested agent.
      • ONE of the following

        • Statin intolerance, defined as ONE of the following

          • Statin-related rhabdomyolysis.
          • Statin-related skeletal muscle symptoms, such as myopathy or myalgia.
          • Statin-related elevated hepatic transaminase.
    • ONE of the following when the patient has an FDA-labeled indication

      • The patient's age is within FDA labeling for the requested indication for the requested agent.
      • There is support for using the requested agent for the patient's age for the requested indication.
    • ONE of the following

      • The requested agent is a preferred agent.
      • The requested agent is a non-preferred agent and the patient has tried and had an inadequate response to ONE preferred agent, or has an intolerance or hypersensitivity to ONE preferred agent, or has an FDA-labeled contraindication to ALL preferred agents.

        Chart notes are required.

    Continuation Therapy

    Target Agent(s) will be approved for 12 months when ALL of the following are met:

    ALL of the following

    • The patient has been previously approved for a PCSK9 inhibitor through the plan's Prior Authorization process.

      Patients not previously approved for a PCSK9 inhibitor require initial evaluation review.

    • The patient has had clinical benefit with a PCSK9 inhibitor.
    • If the patient has a diagnosis of ASCVD, HeFH, hypercholesterolemia, or reduction in the risk of MACE, ONE of the following

      • The patient does not require additional therapy because the goal of therapy has been met using a single-agent PCSK9 inhibitor.
      • ALL of the following

    The requested agent may not be used in combination with another PCSK9 agent.

    The requested agent is not covered when an FDA-labeled contraindication applies to the patient.

    Clinical Thresholds

    HoFH LDL-C threshold
    Threshold> 400 mg/dL
    Applies toUntreated LDL-C for homozygous familial hypercholesterolemia (HoFH)
    Clinical pathwayUsed with qualifying xanthoma or parental LDL-C evidence when genetic confirmation is not used
    HeFH pre-treatment LDL-C threshold
    Threshold> 190 mg/dL
    Applies toPre-treatment LDL-C for heterozygous familial hypercholesterolemia (HeFH)
    Diagnostic roleOne qualifying biochemical finding supporting HeFH

    Authorization and Documentation Guidance

    Prior Authorization

    Initial Prior Authorization Criteria

    For initial approval, document that the patient has a covered diagnosis or supported indication and meets the applicable treatment pathway. Covered pathways include HoFH, HeFH, hypercholesterolemia, ASCVD, reduction in MACE risk, another FDA-labeled indication, or an indication supported by compendia for the requested agent and route.

    • For HoFH, document that the requested agent is Praluent or Repatha and provide qualifying genetic or clinical evidence.
    • For HeFH, provide qualifying evidence such as a pathogenic variant, pretreatment LDL-C >190 mg/dL, clinical manifestations, Simon Broome criteria, a Dutch Lipid Clinic Network score >5, or treated LDL-C ≥100 mg/dL after statin therapy with or without ezetimibe.
    • For ASCVD, document acute coronary syndrome, myocardial infarction, angina, revascularization, stroke, transient ischemic attack, or peripheral arterial disease/aortic aneurysm presumed atherosclerotic in origin.
    • Document maximally tolerated statin therapy with planned continuation, or statin intolerance, statin hypersensitivity, or an FDA-labeled contraindication to all statins.
    • For FDA-labeled indications, confirm that the patient’s age is within labeling or provide support for use at the patient’s age. For compendia-supported use, provide AHFS or DrugDex level 1, 2a, or 2b evidence where applicable.

    Policy Background

    PCSK9 inhibitors are lipid-lowering therapies used in the management of familial hypercholesterolemia and hypercholesterolemia, including homozygous and heterozygous familial hypercholesterolemia. They may also be used for patients with clinical atherosclerotic cardiovascular disease or for reduction of major adverse cardiovascular events (MACE) when the requested product has an applicable FDA-labeled or compendia-supported indication. The policy generally expects maximally tolerated statin therapy with the PCSK9 inhibitor, unless statin intolerance, hypersensitivity, or an FDA-labeled contraindication supports an alternative pathway.

    Clinical Definitions

    MACE
    TermMajor adverse cardiovascular events (MACE)
    Included eventCardiovascular death, myocardial infarction, or stroke
    Included eventUnstable angina requiring hospitalization or coronary revascularization
    ASCVD
    TermClinical atherosclerotic cardiovascular disease (ASCVD)
    Coronary conditionsAcute coronary syndrome, myocardial infarction, stable or unstable angina, or coronary revascularization
    Other qualifying conditions

    Initial Therapy

    Initial Therapy Criteria

    Initial evaluation: approval requires all of the following.

    Initial therapy requirements

    • Covered indication

      • Homozygous familial hypercholesterolemia: The patient has HoFH, the requested agent is Praluent or Repatha, and HoFH is confirmed by qualifying genetic evidence or by a history of untreated LDL-C greater than 400 mg/dL plus qualifying xanthoma or parental LDL-C evidence.Untreated LDL-C > 400 mg/dL for the clinical confirmation pathway

        Genetic confirmation requires bi-allelic pathogenic or likely pathogenic variants on different chromosomes at the LDLR, Apo-B, PCSK9, or LDLRAP1 genes, or at least two such variants at different loci.

      • Heterozygous familial hypercholesterolemia

        • Qualifying HeFH evidence:

    Continuation Therapy

    PCSK9 Inhibitor Renewal Criteria

    Renewal evaluation: approval requires all of the following.

    PCSK9 inhibitor renewal requirements

    • Ongoing lipid-management pathway

      • Goal achieved with single agent: The patient has met the treatment goal using a single PCSK9 inhibitor and does not require additional therapy.
      • Continued statin therapy: The patient is taking a maximally tolerated statin and will continue statin therapy in combination with the requested agent.
      • Statin alternative pathway: The patient is statin intolerant because of statin-related rhabdomyolysis, statin-related skeletal muscle symptoms, or statin-related elevated hepatic transaminases; has hypersensitivity to one statin; or has an FDA-labeled contraindication to all statins.

    Preferred-Agent Requirements

    StepRequirementException criteria and documentation
    1A non-preferred agent requires an exception to the preferred-agent requirement.The patient must have tried and had an inadequate response to one preferred agent, experienced intolerance or hypersensitivity to one preferred agent, or had an FDA-labeled contraindication to all preferred agents. Chart notes are required.

    Product Quantity Limits

    Lerochol quantity limit
    Quantity limit1 syringe per 28 days
    Strength300 mg/1.2 mL
    Dosage formPrefilled syringe
    Lipfendra quantity limit
    Quantity limit30 tablets per 30 days
    Strength20 mg
    Dosage formTablet
    Policy Summary
    PayerPrime Therapeutics
    PolicyPCSK9 Inhibitors Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 19, 2026
    Next Review DateN/A
    Key ActionSubmit documentation supporting the diagnosis, LDL-C values, ASCVD history, statin treatment or intolerance, and the requested agent's indication.
    SourceLink
    On This Page
    Coverage CriteriaClinical ThresholdsAuthorization and Documentation GuidancePolicy BackgroundClinical DefinitionsInitial TherapyContinuation TherapyPreferred-Agent RequirementsProduct Quantity Limits
    Peripheral arterial disease, including aortic aneurysm, presumed to be of atherosclerotic origin.
  1. Hypersensitivity to ONE statin.
  2. An FDA-labeled contraindication to ALL statins.
  3. The patient is taking a maximally tolerated statin.
  4. The patient will continue statin therapy in combination with the requested agent.
  5. ONE of the following

    • Statin intolerance, defined as ONE of the following

      • Statin-related rhabdomyolysis.
      • Statin-related skeletal muscle symptoms, such as myopathy or myalgia.
      • Statin-related elevated hepatic transaminase.
    • Hypersensitivity to ONE statin.
    • An FDA-labeled contraindication to ALL statins.
  6. Dutch Lipid Clinic Network score
    Threshold> 5
    AssessmentDutch Lipid Clinic Network Criteria score
    Diagnostic roleOne qualifying diagnostic-criteria finding supporting HeFH
    HeFH treated LDL-C threshold
    Threshold>= 100 mg/dL
    Applies toTreated LDL-C for heterozygous familial hypercholesterolemia (HeFH)
    Treatment historyAfter statin treatment with or without ezetimibe
    Prior Authorization

    Initial Approval Duration

    Initial approvals are authorized for 12 months. Where the request relies on a compendia-supported indication, submit the applicable AHFS or DrugDex level 1, 2a, or 2b evidence.

    • If a quantity limit applies, the request must also satisfy the applicable Quantity Limit Criteria.
    Prior Authorization

    Renewal Prior Authorization

    Renewal requires prior plan approval for a PCSK9 inhibitor, demonstrated clinical benefit, and continued satisfaction of the applicable diagnosis, treatment, agent-selection, safety, and combination-use requirements.

    • Patients without prior plan approval require initial-evaluation review.
    • Renewal approval is for 12 months.
    • If the patient has ASCVD, HeFH, hypercholesterolemia, or a MACE-risk indication, document that therapy goals are met with a single PCSK9 inhibitor or that the applicable statin or statin-exception pathway remains satisfied.
    Step Therapy

    Preferred PCSK9 Agent Trial

    A non-preferred agent requires a documented trial of a preferred PCSK9 agent unless an accepted exception applies. The preferred agents are Repatha (evolocumab) and Praluent (alirocumab); non-preferred agents include Lerochol (lerodalcibep-liga) and Lipfendra (enlicitide).

    • Document that the patient tried one preferred agent and had an inadequate response.
    • Alternatively, document intolerance or hypersensitivity to one preferred agent, or an FDA-labeled contraindication to all preferred agents.
    • The same preferred-agent requirement and exception pathway applies at renewal.
    Documentation Required

    Clinical Diagnosis and Treatment Documentation

    Submit clinical records supporting the diagnosis, familial hypercholesterolemia evidence when applicable, and relevant treatment history. Documentation should allow review of the indication, laboratory or genetic evidence, prior therapy, and response.

    • For HoFH, provide genetic confirmation of bi-allelic pathogenic or likely pathogenic variants at qualifying loci, or untreated LDL-C >400 mg/dL with qualifying xanthoma or parental LDL-C history.
    • For HeFH, provide genetic, LDL-C, clinical-manifestation, Simon Broome, Dutch Lipid Clinic Network, or treated LDL-C evidence as applicable.
    • Document cardiovascular history for ASCVD or MACE-risk requests and identify the requested agent and route of administration.
    • Include statin treatment history, maximally tolerated dose or rationale for intolerance, hypersensitivity, or contraindication.
    Documentation Required

    Preferred-Agent Exception Documentation

    For a non-preferred agent, chart notes are required to support the exception to preferred-agent sequencing. The record must clearly identify the preferred agent and the clinical reason it cannot be used or was inadequate.

    • Document an inadequate response after a trial of one preferred agent, including relevant treatment dates and clinical or laboratory response.
    • Document intolerance or hypersensitivity to one preferred agent, including the reaction and its clinical significance.
    • Document an FDA-labeled contraindication to all preferred agents when that is the basis for the exception.
    Documentation Required

    Renewal Documentation

    Renewal requests must include the prior approval or authorization history, evidence of clinical benefit, and documentation that the patient remains appropriately treated.

    • Confirm prior plan approval for a PCSK9 inhibitor; otherwise submit an initial request.
    • Document current therapy and clinical response or achievement of treatment goals.
    • Document continued maximally tolerated statin therapy and planned continuation, or current statin intolerance, hypersensitivity, or FDA-labeled contraindication to all statins.
    • For non-preferred therapy, include current preferred-agent exception documentation and confirm no concurrent PCSK9 agent or FDA-labeled contraindication to the requested agent.
    Documentation Required

    Quantity-Limit Exception Documentation

    For a quantity-limit exception, document that the requested dose is clinically supported and complies with the FDA-labeled maximum dose requirements for the indication.

    • If the requested agent has no maximum FDA-labeled dose for the indication, provide support for therapy with the higher dose.
    • If a maximum FDA-labeled dose applies, confirm the requested quantity does not exceed it and explain why the quantity cannot be achieved with a lower quantity of a higher strength that remains within the program quantity limit.
    • Quantity-limit approvals are authorized for 12 months.
    Denial Risk

    Non-Preferred Agent Without Exception

    Requests for a non-preferred agent may be denied when the required preferred-agent trial or an accepted exception is not documented.

    • Submit evidence of an inadequate response to one preferred agent, intolerance or hypersensitivity to one preferred agent, or an FDA-labeled contraindication to all preferred agents.
    • A preference exception must be supported by chart notes; an unsupported request for a non-preferred agent does not satisfy the criteria.
    Denial Risk

    Combination Use or Contraindication

    Approval may be denied when the requested agent will be used with another PCSK9 agent or when the patient has an FDA-labeled contraindication to the requested agent.

    • Confirm that the patient will not use the requested agent concurrently with another PCSK9 inhibitor.
    • Review the prescribing information and document absence of FDA-labeled contraindications.
    • The same combination-use and contraindication requirements apply to initial and renewal requests.
    Denial Risk

    Insufficient Indication or Treatment History

    A request may be denied when the record does not establish a covered diagnosis or supported indication, adequate familial hypercholesterolemia evidence, or the required treatment history.

    • Provide the applicable HoFH, HeFH, hypercholesterolemia, ASCVD, MACE-risk, FDA-labeled, or compendia-supported indication.
    • For HoFH or HeFH, include the required genetic, LDL-C, clinical, or validated diagnostic evidence.
    • Document maximally tolerated statin therapy and continuation, or qualifying statin intolerance, hypersensitivity, or contraindication to all statins.
    • For FDA-labeled indications, provide age eligibility or support for use at the patient’s age; for compendia-supported use, provide qualifying evidence.
    Denial Risk

    Renewal Without Prior Approval or Benefit

    Renewal may be denied when the patient lacks prior plan authorization for a PCSK9 inhibitor or when continued clinical benefit is not demonstrated.

    • Patients not previously approved require initial-evaluation review.
    • Submit objective or clinical evidence of benefit with the current PCSK9 inhibitor.
    • Confirm ongoing satisfaction of the applicable statin, preferred-agent, combination-use, and contraindication criteria.
    Denial Risk

    Unsupported Quantity-Limit Exception

    A quantity-limit exception may be denied when the requested higher dose or quantity is not supported by FDA labeling and clinical documentation.

    • The requested quantity must not exceed the FDA-labeled maximum dose for the indication, unless no labeled maximum dose exists and higher-dose therapy is supported.
    • When a labeled maximum applies, explain why the request cannot be met with a lower quantity of a higher strength within the program quantity limit.
    • Requests lacking clinical support for the higher quantity do not meet the exception criteria.
    Arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease including presumed atherosclerotic aortic aneurysm
    HoFH
    TermHomozygous familial hypercholesterolemia (HoFH)
    Genetic confirmationQualifying bi-allelic pathogenic or likely pathogenic variants
    Clinical confirmationUntreated LDL-C > 400 mg/dL plus qualifying xanthoma or parental LDL-C evidence
    HeFH
    TermHeterozygous familial hypercholesterolemia (HeFH)
    Genetic or clinical supportOne mutant allele, pre-treatment LDL-C > 190 mg/dL, clinical xanthomas or corneal arcus, or definite or possible Simon Broome criteria
    Diagnostic supportDutch Lipid Clinic Network score > 5 or treated LDL-C >= 100 mg/dL after statin treatment with or without ezetimibe
    Statin intolerance
    TermStatin intolerance
    Muscle-related conditionsStatin-related rhabdomyolysis or skeletal muscle symptoms such as myopathy or myalgia
    Other qualifying conditionsStatin-related elevated hepatic transaminase, hypersensitivity to one statin, or an FDA-labeled contraindication to all statins
    Evidence includes one mutant allele; pre-treatment LDL-C greater than 190 mg/dL; clinical manifestations such as cutaneous or tendon xanthomas or corneal arcus; definite or possible Simon Broome criteria; a Dutch Lipid Clinic Network score greater than 5; or treated LDL-C at least 100 mg/dL after statin treatment with or without ezetimibe.
    Pre-treatment LDL-C > 190 mg/dL; Dutch Lipid Clinic Network score > 5; or treated LDL-C >= 100 mg/dL after statin treatment with or without ezetimibe
  7. Other covered indications: The patient has hypercholesterolemia; requires reduction in the risk of MACE with Praluent or Repatha; has clinical ASCVD with a qualifying event or disease; has another FDA-labeled indication for the requested agent and route; or has a compendia-supported indication for the requested agent and route.

    Qualifying ASCVD includes acute coronary syndrome, myocardial infarction, stable or unstable angina, coronary or arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease including presumed atherosclerotic aortic aneurysm.

  8. Statin pathway

    • Alternative statin pathway: The patient has statin-related rhabdomyolysis, statin-related skeletal muscle symptoms such as myopathy or myalgia, statin-related elevated hepatic transaminases, hypersensitivity to one statin, or an FDA-labeled contraindication to all statins.
  9. Age requirement: When an FDA-labeled indication is used, the patient's age is within FDA labeling for the requested indication or there is support for using the requested agent at the patient's age for that indication.
  10. Preferred-agent requirement: The requested agent is preferred, or the requested non-preferred agent is supported by chart notes documenting an inadequate response to one preferred agent, intolerance or hypersensitivity to one preferred agent, or an FDA-labeled contraindication to all preferred agents.
  11. Safety and combination requirements: The requested agent will not be used in combination with another PCSK9 agent, and the patient does not have an FDA-labeled contraindication to the requested agent.
  12. Preferred-agent requirement: The requested agent is preferred, or the requested non-preferred agent is supported by chart notes documenting an inadequate response to one preferred agent, intolerance or hypersensitivity to one preferred agent, or an FDA-labeled contraindication to all preferred agents.
  13. Safety requirements: The requested agent will not be used in combination with another PCSK9 agent, and the patient does not have an FDA-labeled contraindication to the requested agent.
  14. Praluent quantity limit
    Quantity limit2 pens per 28 days
    Strength75 mg/mL or 150 mg/mL
    Dosage formPen
    Repatha prefilled syringe quantity limit
    Quantity limit6 syringes per 28 days
    Strength140 mg/mL
    Dosage formPrefilled syringe
    Repatha Pushtronex quantity limit
    Quantity limit2 cartridges per 28 days
    Strength420 mg/3.5 mL
    Dosage formCartridge/infusor
    Repatha SureClick quantity limit
    Quantity limit6 pens per 28 days
    Strength140 mg/mL
    Dosage formAuto-injector pen